Another possible cause of rosacea is the increased presence of a common microscopic mite called Demodex folliculorum. This mite is more abundant on the skin of people with rosacea. According to ...

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

A Phase II study for ocular rosacea is set to begin in late 2025, with data expected in 2026. Tarsus aims to expand physician education to identify Demodex blepharitis in broader patient categories.

Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the ...

XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular ...

INDICATIONS AND USAGEXDEMVY is indicated for the treatment of Demodex blepharitis ... TP-04 for the potential treatment of Ocular Rosacea. About TP-05TP-05 is an investigational oral systemic ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the ...

As Bobby noted, we are extremely excited about Ocular Rosacea. Because like DB, it is caused by Demodex mites and can impact how we look, feel and see. It can also be quickly and simply diagnosed ...